⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PLRZ News
Polyrizon Ltd. Ordinary Shares
Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial
globenewswire.com
PLRZ
Pulse Equity: Emerging Outbreaks - Polyrizon's Approach to Broad and Rapidly Deployable Protection
prnewswire.com
PLRZ
Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform
globenewswire.com
PLRZ
Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform
globenewswire.com
PLRZ
Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements
globenewswire.com
PLRZ
Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement
globenewswire.com
PLRZ
Polyrizon Provides 2025 and Recent Highlights
globenewswire.com
PLRZ
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
globenewswire.com
PLRZ
Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications
globenewswire.com
PLRZ
Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program
globenewswire.com
PLRZ